Develops CRISPR gene-editing medicines, with an approved sickle cell treatment sold with Vertex.
$49.25close as of 2026-10-16
-28.0% over 1Y · 44.8 points behind the S&P 500
CRSPS&P 500 (SPY), rebased to CRSP's first close
“Can broader CASGEVY access reduce the Vertex collaboration’s remaining expense as CRISPR advances its clinical pipeline?”
Editorial note · updated 2026-10-08
The TenQ Radar
CRISPR Therapeutics in 36 checks
CRISPR Therapeutics on the TenQ Radar: value, growth, quality, health, shareholder returns and trend. The fuller the shape, the stronger the company. Behind each axis are six pass-or-fail checks from its filings, spelled out in the chapters below. Point at an axis to see them.
The business itself is the question here: 5 of 36 checks passed.
The CRISPR Therapeutics story
What drives CRISPR Therapeutics, what its price assumes and what could change the story, written from its own filings.
CASGEVY access expands. CASGEVY generated $76 million in product revenue in the quarter to June 2026, with U.S. approval extended to children as young as 2 years old.
Commercial growth still costs. CRISPR reported net collaboration expense of $40.3 million in the quarter to June 2026, despite an increase in its share of CASGEVY revenue.
Financing adds cash. Convertible notes issued in March 2026 raised $585.4 million in net proceeds, helping bring cash, cash equivalents, and marketable securities to $2,364.4 million as of June 30, 2026.
Q2 '26 · quarter to 30 June 2026 · reported 3 August 2026 · Earnings release ↗
Revenue$10M+1041%vs 2025+598%vs Q1
Earnings-$91M+$117Mvs 2025+$32Mvs Q1
What the release says
Highlights
CASGEVY generated $76 million in revenue for the second quarter of 2026, representing 78% growth quarter-over-quarter and 151% growth year-over-year, driven by expanded approvals and reimbursement progress.
The U.S. FDA approved CASGEVY for children as young as 2 years old with sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT), making it the first genetic therapy indicated for this age group and potentially expanding the eligible patient pool by approximately 5,500 in the U.S.
CRISPR Therapeutics initiated Phase 1 clinical trials for two new in vivo gene editing candidates: CTX340 for refractory hypertension and CTX460 for alpha-1 antitrypsin deficiency, further diversifying its pipeline.
The company strengthened its cash position to $2,364.4 million as of June 30, 2026, primarily due to $585.4 million in net proceeds from a convertible senior notes issuance, while reducing its net loss to $91.2 million from $208.5 million in the prior year quarter.
What management expects
The company expects to provide clinical updates on CTX310 (ANGPTL3) and CTX611 (FXI) in the second half of 2026.
Updates on the zugo-cel autoimmune and immuno-oncology programs, as well as the Lp(a) program, are also anticipated in the second half of 2026.
CRISPR Therapeutics expects to provide additional updates on its regenerative medicine program in diabetes as development progresses.
Key risks
CRISPR Therapeutics expects to continue incurring significant and increasing operating losses for the foreseeable future, as expenses for development and commercialization of CASGEVY and other programs are anticipated to exceed revenue.
The company will need to raise substantial additional funding to support its operations and pipeline, and if unable to do so, may be forced to delay, reduce, or eliminate some product development or commercialization efforts.
There is uncertainty regarding the ability to advance product candidates through clinical development, obtain regulatory approval, and successfully commercialize them, which could materially harm the business if not achieved.
Gene editing technologies, including CRISPR/Cas9 and in vivo therapies, are relatively new and unproven, making it difficult to predict development timelines, costs, and regulatory outcomes, and there may be unforeseen long-term safety risks.
AI summary of the company's filings, every number checked against them · 8 October 2026 · Sources: earnings release, 10-K, 10-Q
Earnings alerts
An email when CRISPR Therapeutics reports, with its results and highlights. Free with a watchlist account.
I
Value
●●●●●●0/6
Expensive against its own history and its sector (judged on sales, as it is not yet profitable): the price asks a lot of the business.
-no history
355.6xown 9-year median 128.1x
-7.8%cash earned per $ of price
-whole-business multiple
Valuation history
Is CRSP's P/E, P/S or P/B high or low against its own past?
Year
P/E
P/S
P/B
2019
37.7772
8.7217
2.6886
2021
25.7658
10.6351
4.0554
2026
-
355.5939
2.7266
◌ 2026 = at the latest close (2026-10-16), over the trailing twelve months; earlier years are annual averages · the last point is at the latest close (2026-10-16); earlier quarters use that quarter's average price over the trailing twelve months to it
→At 355.6x sales, the market is paying +178% more than CRSP's own 9-year median of 128.1x. Expectations are elevated, so more has to go right to justify the price.
What this measures
What the market has paid for each dollar of earnings, sales or book value, every year, with today's multiple as the last point and the median drawn across.
What good looks like. There is no good level. What matters is the distance from the company's own history, and whether the business has changed enough to justify it.
If it rises or falls. A multiple above its own median means the market expects more than it used to, so more has to go right. Below the median means the opposite, and the question is whether the pessimism is deserved. A multiple can also fall because earnings rose, which is the good way.
Free cash flow yield
What is CRSP's free cash flow yield at today's price?
Period
FCF yield
2017
-0.1062
2018
-0.0445
2019
0.0198
2020
-0.0489
2021
0.047
2022
-0.1109
2023
-0.0643
2024
-0.0303
2025
-0.0772
2026
-0.078
◌ 2026 = at the latest close (2026-10-16), over the trailing twelve months; earlier years are annual averages · the last point is at the latest close (2026-10-16); earlier quarters use that quarter's average price over the trailing twelve months to it
→Every dollar of market value currently buys -7.8% of annual free cash flow, more than its 9-year median of -4.9% - the cash is cheaper than usual.
What this measures
Free cash flow divided by market value: the cash the business generates for every dollar you pay for it. The inverse of a price-to-cash multiple.
What good looks like. A yield at or above the company's own history, and one that compares well with what cash is worth elsewhere.
If it rises or falls. The yield rises when cash grows or the price falls, so a high yield is either a bargain or a warning about the cash continuing. Read it beside the cash conversion chart, which shows whether the cash is holding up.
What does “Value” actually mean?
Value asks what you pay for each dollar of earnings, sales or cash the business produces. A high multiple isn't automatically bad - fast growers earn theirs - but a price far above the company's own history means the market expects a lot to go right. We compare each multiple to the company's own past and to its sector, never to a universal rule.
not profitable: no free cash flow or earnings for the price to rest on
II
Growth
●●●●●●2/6
Growth is weak or inconsistent. The trend, not the story, is the problem.
-64.8%vs the year before
+43.1%compound annual
-net income growth
-compound annual
Revenue history
Is CRSP's revenue growing?
◌ dashed quarter = Q4 derived from the annual filing minus Q1, Q2 and Q3 (the SEC never receives a Q4 report)
Period
Revenue ($)
Q4 2015
247,000
Q1 2016
476,000
Q2 2016
795,000
Q3 2016
1.5M
Q4 2016
2.3M
Q1 2017
2.7M
Q2 2017
3.6M
Q3 2017
2.4M
Q4 2017
32.3M
Q1 2018
1.4M
Q2 2018
1.1M
Q3 2018
563,000
Q4 2018
115,000
Q1 2019
328,000
Q2 2019
318,000
Q3 2019
211.9M
Q4 2019
77.0M
Q1 2020
157,000
Q2 2020
44,000
Q3 2020
148,000
Q4 2020
370,000
Q1 2021
539,000
Q2 2021
900.7M
Q3 2021
824,000
Q4 2021
12.9M
Q1 2022
940,000
Q2 2022
158,000
Q3 2022
94,000
Q4 2022
6,000
Q1 2023
100.0M
Q2 2023
70.0M
Q3 2023
0
Q4 2023
201.2M
Q1 2024
504,000
Q2 2024
517,000
Q3 2024
602,000
Q4 2024
35.7M
Q1 2025
865,000
Q2 2025
892,000
Q3 2025
889,000
Q4 2025
864,000
Q1 2026
1.5M
Q2 2026
10.2M
2015
247,000
2016
5.2M
2017
41.0M
2018
3.1M
2019
289.6M
2020
719,000
2021
915.0M
2022
1.2M
2023
371.2M
2024
37.3M
2025
3.5M
→Revenue reached $4M in 2025, compounding +43% a year since 2022 and the pace is picking up. The last twelve months (-65%) ran below that pace, so growth is slowing. The trailing twelve months are already running at $13M, ahead of the last full year.
What this measures
The money customers paid, before any costs are taken out. Each bar is one quarter or, on the annual view, a full financial year; the last annual bar may be the trailing twelve months, which the footnote marks.
What good looks like. Growth that repeats, rather than one strong year carrying the chart, and a trailing twelve months keeping pace with the last full year.
If it rises or falls. Revenue is the hardest line to flatter, so a rise is the most trustworthy kind of growth. A fall puts pressure on every margin below it, because costs rarely come down as quickly as sales do.
Revenue by productInsight
Where does CRISPR Therapeutics' revenue come from?
dashed quarter = Q4 derived from the annual filing minus Q1, Q2 and Q3 (the SEC never receives a Q4 report)
→CRISPR Therapeutics makes 98% of its revenue from Collaboration Revenue ($10M), and that share has risen from 40% in 2021Q3: the mix is shifting towards Collaboration Revenue.
Source: SEC filings - segment disclosures (XBRL notes) · as at 2026-06-30
Profit history
Is CRSP's net profit growing?
◌ dashed quarter = Q4 derived from the annual filing minus Q1, Q2 and Q3 (the SEC never receives a Q4 report)
Period
Net income ($)
Q1 2015
-3.2M
Q2 2015
-3.6M
Q3 2015
-6.4M
Q4 2015
-12.3M
Q1 2016
-8.4M
Q2 2016
-17.2M
Q3 2016
-14.7M
Q4 2016
17.1M
Q1 2017
-21.5M
Q2 2017
-22.3M
Q3 2017
-24.7M
Q4 2017
140,000
Q1 2018
-28.3M
Q2 2018
-38.4M
Q3 2018
-50.7M
Q4 2018
-47.6M
Q1 2019
-48.4M
Q2 2019
-53.7M
Q3 2019
138.4M
Q4 2019
30.5M
Q1 2020
-69.7M
Q2 2020
-79.7M
Q3 2020
-92.4M
Q4 2020
-107.0M
Q1 2021
-113.2M
Q2 2021
759.2M
Q3 2021
-127.2M
Q4 2021
-141.2M
Q1 2022
-179.2M
Q2 2022
-185.8M
Q3 2022
-174.5M
Q4 2022
-110.6M
Q1 2023
-53.1M
Q2 2023
-77.7M
Q3 2023
-112.2M
Q4 2023
89.3M
Q1 2024
-116.6M
Q2 2024
-126.4M
Q3 2024
-85.9M
Q4 2024
-37.3M
Q1 2025
-136.0M
Q2 2025
-208.5M
Q3 2025
-106.4M
Q4 2025
-130.6M
Q1 2026
-122.9M
Q2 2026
-91.2M
2014
-7.0M
2015
-25.5M
2016
-23.2M
2017
-68.4M
2018
-165.0M
2019
66.9M
2020
-348.9M
2021
377.7M
2022
-650.2M
2023
-153.6M
2024
-366.3M
2025
-581.6M
→The company lost $582M in 2025, more than the $366M it lost the year before. The losses are widening - check the Health chapter for how long the cash lasts.
What this measures
What is left after every cost, including tax and interest. The bottom line of the income statement.
What good looks like. Profit growing at least as fast as revenue, which means the business is keeping more of each sale as it gets bigger.
If it rises or falls. Profit can move for reasons revenue cannot explain - a one-off charge, a tax change, a write-down - so a single sharp year is worth checking against the margin chart before reading it as a trend.
Growth rate
How fast are CRSP's revenue and earnings growing?
Shown separately because they would flatten the axis: 2020 earnings -622% · 2022 earnings -272% - rebounds off a collapsed prior year.
Year
Revenue growth
Earnings growth
2,016
19.9069
-
2,017
6.939
-
2,018
-0.9238
-
2,019
91.6985
-
2,020
-0.9975
-
2,021
1,272
-
2,022
-0.9987
-
2,023
308.8548
-
2,024
-0.8995
-
2,025
-0.9059
-
2026
-0.648
-
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · on the quarterly views, growth is the trailing twelve months against the twelve before, or a quarter against the same quarter a year earlier
→Revenue fell 65% over the twelve months to 2026-06-30, against an average of +31552% a year over 2021-2025.
What this measures
How much revenue and earnings changed against the year before - the trailing twelve months against the twelve before them at each quarter, or one point per fiscal year. It is the speed of the business, not its size.
What good looks like. The earnings line above the revenue line: profits growing faster than sales means each new dollar of sales arrives more profitably than the last.
If it rises or falls. A high growth rate off a small base is easy and gets harder every year, so slowing growth in a large business is normal rather than a warning. Earnings falling while revenue grows is the combination worth understanding: costs are rising faster than sales.
Per-share growth
Are CRSP's revenue and free cash flow per share growing?
Year
Revenue per share ($)
Free cash flow per share ($)
2,017
1.0235
-1.9449
2,018
0.0651
-2.0643
2,019
5.0865
0.8781
2,020
0.0109
-3.8927
2,021
11.3811
5.6879
2,022
0.0154
-6.8547
2,023
4.6857
-3.4062
2,024
0.4423
-1.715
2,025
0.039
-3.8468
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→Revenue per share reached $0.04 in 2025, compounding +36% a year against +43% for CRSP as a whole. Dilution absorbed about 6.8 points of that growth. The trailing twelve months are running at $0.15 a share. Free cash flow per share stands at $-3.85.
What this measures
Revenue and free cash flow, each divided by the number of shares in issue and adjusted for splits so old and new years compare honestly. Both lines rising means each share owns more of the business's sales and cash.
What good looks like. Both lines rising, and revenue per share growing at least as fast as the company's total revenue, which the answer compares. Faster means buybacks are working for you; slower means new shares are absorbing part of the growth.
If it rises or falls. This is the line that actually reaches you. A company can grow revenue every year and still shrink your slice by issuing shares faster than it grows.
What does “Growth” actually mean?
Growth here is what the company has actually reported to the SEC - not a forecast. We look at the last year, the three-year pace, whether growth is speeding up or slowing down, and whether it's been consistent rather than one lucky year. Hatched bars are fourth quarters we derived from annual filings (companies file a full-year 10-K rather than a Q4 report).
Profitability is thin or negative. The growth isn't turning into money yet.
-kept after direct costs
-3990.0%kept after running costs
-24.8%profit on shareholders' money
-21.2%against a 10% cost of capital
-operating cash ÷ net income
Margins
What profit margin does CRSP keep on each sale?
Year
Gross
Operating
Net
2,015
-
-104.166
-103.251
2,016
-
-13.1933
-4.4882
2,017
-
-1.5769
-1.6674
2,018
-
-50.878
-52.8108
2,019
-
0.1614
0.2309
2,020
-
-492.9555
-485.2086
2,021
-
0.4082
0.4128
2,022
-
-561.904
-542.717
2,023
-
-0.5995
-0.4138
2,024
-
-12.5038
-9.8154
2,025
-
-189.3365
-165.6977
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→Operating margin widened 37257 points to -18934% since 2022. The bottom line is still negative: costs below the operating line eat what is left. CRSP doesn't tag a gross-profit line in its filings, so the chart starts at operating margin.
What this measures
What survives at three points on the way down the income statement: after the direct cost of the product, after the cost of running the company, and after everything.
What good looks like. Margins that hold or widen as the business grows. The level itself varies enormously by industry, so the shape over time tells you more than the number.
If it rises or falls. A widening margin means pricing power or costs under control. A compressing one means the opposite, and it compounds: on large revenue, two points of margin is a great deal of profit.
Earnings quality
Does CRSP's operating cash flow keep up with its profit?
Year
Cash from operations
Net income
2,014
-4.8M
-7.0M
2,015
59.4M
-25.5M
2,016
-52.9M
-23.2M
2,017
-70.1M
-68.4M
2,018
-96.2M
-165.0M
2,019
56.7M
66.9M
2,020
-238.4M
-348.9M
2,021
539.0M
377.7M
2,022
-495.7M
-650.2M
2,023
-260.4M
-153.6M
2,024
-142.8M
-366.3M
2,025
-345.0M
-581.6M
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→The company generated -$345M of operating cash in 2025. With no profit to compare against, cash generation is the number that matters here.
What this measures
Reported profit against the cash the business actually collected from operating. Profit is an accounting judgement; cash is not.
What good looks like. Cash at or above profit, year after year. Depreciation and other non-cash charges usually push cash above profit, so roughly 100% or more is healthy.
If it rises or falls. Cash falling behind profit for more than a year is the classic early warning: the sales are booked but the money has not arrived, and it shows up in receivables and inventory. For a lender the comparison behaves differently, because a growing loan book consumes cash.
Returns on capital
What return on equity and on capital does CRSP earn?
Year
ROE
ROA
ROCE
2,017
-0.325
-0.2519
-0.2517
2,018
-0.5689
-0.3374
-0.3446
2,019
0.1004
0.0627
0.0463
2,020
-0.268
-0.1908
-0.2044
2,021
0.1859
0.1372
0.1419
2,022
-0.3042
-0.2899
-0.3172
2,023
-0.0817
-0.0689
-0.1049
2,024
-0.192
-0.1634
-0.2166
2,025
-0.3018
-0.2567
-0.3141
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→ROE of -25% and ROCE of -21% sit close together, so the returns come from the business itself rather than from borrowing.
What this measures
Two returns side by side: on shareholders' capital (ROE), and on all the capital in the business including debt (ROCE).
What good looks like. Both comfortably above roughly 10%, and close together. A wide gap means borrowing, not operations, is doing the work.
If it rises or falls. A high ROE built on debt looks like quality until the debt has to be refinanced. ROCE is the harder number to flatter, which is why both are shown.
Cash conversion
How much of each sale does CRSP turn into free cash flow?
Period
FCF margin
2015
235.9271
2016
-10.8203
2017
-1.9003
2018
-31.694
2019
0.1726
2020
-357.057
2021
0.4998
2022
-444.8489
2023
-0.7269
2024
-3.8772
2025
-98.555
→Free cash flow is negative, so no share of revenue is currently converting to spare cash. Every sales dollar is being reinvested or consumed.
What this measures
Free cash flow as a share of revenue: how much of each dollar of sales survives both costs and capital spending.
What good looks like. A steady or rising share. Asset-light businesses convert far more than manufacturers, so compare a company with itself.
If it rises or falls. Falling conversion while revenue grows means growth is being bought with capital spending or working capital, which is fine while it lasts and painful when it stops.
Spending intensity
How much of its revenue does CRSP spend on capex, R&D and stock pay?
Year
Capex % of rev
R&D % of rev
Stock comp % of rev
2,015
4.6721
50.9028
14.915
2,016
0.584
8.1793
2.0999
2,017
0.1906
1.7026
0.4604
2,018
0.8876
36.419
11.1988
2,019
0.0231
0.6194
0.1521
2,020
25.5327
307.9026
91.8192
2,021
0.0893
0.3722
0.1119
2,022
31.0417
385.3464
81.7588
2,023
0.0255
1.0434
0.2183
2,024
0.0509
8.3142
2.32
2,025
0.2604
81.1413
20.655
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→The biggest claim on each sales dollar is research and development, at 8114% of revenue (stock compensation 2065%, capital spending 26%). That share has fallen since 2022, so the cost of competing is easing.
What this measures
Capital spending, research and development, and stock compensation, each as a share of revenue. The three ways a business pays to keep its position.
What good looks like. A share that is stable or falling while revenue grows, which means the cost of competing is not rising with the business.
If it rises or falls. Rising intensity means each new dollar of sales is getting more expensive to win. Falling intensity can mean efficiency, or it can mean under-investment that shows up years later.
Return on capital employed
Is CRSP's return on capital above what its capital costs?
Period
Return on capital employed
2015
-0.1724
2016
-0.211
2017
-0.2517
2018
-0.3446
2019
0.0463
2020
-0.2044
2021
0.1419
2022
-0.3172
2023
-0.1049
2024
-0.2166
2025
-0.3141
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→CRSP's return on capital is negative at -31.4% in 2025. The capital in the business is not yet earning anything back.
What this measures
The same return as the card above, but every filed year, against a 10% line that stands in for what capital costs.
What good looks like. Years above the line, and a trend that is flat or rising rather than drifting down towards it.
If it rises or falls. A business earning above its cost of capital creates value by growing; one earning below it destroys value by growing. The 10% line is a convention, not a law, so read the distance from it rather than the crossing.
What does “Quality” actually mean?
Quality asks whether the growth makes real money. Margins show how much of each sale survives costs; return on equity shows what shareholders earn on their capital; and the profit-to-cash comparison catches companies whose accounting profits never turn into actual cash.
TTM operating cash flow -$370M on a net loss of $451M
IV
Financial health
●●●●●●3/6
Financially sound overall, with one or two things worth watching.
0.34xborrowed vs owned
17.8xnear-term bills coverage
-earnings ÷ interest bill
$2.4Bcash plus short-term investments
Debt & cash
How much debt does CRSP carry, and do its profits cover the interest?
Year
Total debt
Cash & investments
2,013
-
361,000
2,014
-
945,000
2,015
38.3M
156.0M
2,016
38.3M
315.5M
2,017
-
239.8M
2,018
0
456.6M
2,019
0
943.8M
2,020
0
1.69B
2,021
0
2.38B
2,022
0
1.82B
2,023
0
1.69B
2,024
0
1.90B
2,025
0
1.98B
2,026
586.2M
2.36B
◌ each quarterly point is the balance sheet at that quarter end
→The company holds $2.4B in cash against $586M of debt - a net-cash balance sheet, which means a bad year is an inconvenience rather than a threat.
What this measures
Total borrowings against cash on hand, with debt as a multiple of shareholders' equity, and how many times profit covers the interest bill.
What good looks like. Interest covered comfortably - roughly eight times or more - and debt that is not a large multiple of equity.
If it rises or falls. Debt is only a problem when it has to be repaid or refinanced in a bad year, so cover matters more than the amount. Rising debt with rising cover is a business borrowing to grow; rising debt with falling cover is the combination that ends badly.
Near-term liquidity
Do CRSP's current assets cover the bills due within a year?
Period
Current ratio
2015
15.4446
2016
14.5553
2017
17.117
2018
16.8095
2019
17.2932
2020
18.2117
2021
20.1656
2022
15.3007
2023
17.5389
2024
22.0675
2025
13.3159
◌ 2026 = the latest balance sheet (2026-06-30), not a fiscal year-end · each quarterly point is the balance sheet at that quarter end
→Near-term liquidity is comfortable: 17.8x of current assets for every dollar due within the year. That is stronger than in 2015.
What this measures
Current assets over current liabilities: what the company can turn into cash within a year against what it owes within a year.
What good looks like. Comfortably above 1.0, and not falling year after year. Below 1.0 means near-term bills exceed near-term resources, which is normal for some business models and a warning in others.
If it rises or falls. Inventory and receivables build it up; short-term borrowing and payables pull it down. A retailer that turns stock over quickly can run lower than a manufacturer and be perfectly sound.
Cash conversion
How much of CRSP's revenue arrives as operating cash?
Period
Operating cash flow / revenue
2015
240.5992
2016
-10.2363
2017
-1.7097
2018
-30.8063
2019
0.1957
2020
-331.5243
2021
0.5891
2022
-413.8072
2023
-0.7014
2024
-3.8263
2025
-98.2946
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→CRSP's operations consumed cash rather than produced it over the last twelve months. Down from 24059.9% in 2015.
What this measures
Operating cash flow as a share of revenue: of every dollar sold, how much reached the bank before capital spending.
What good looks like. A high share, holding up or improving. It is the clearest sign that reported profit is real.
If it rises or falls. It falls when customers take longer to pay or stock builds up, and it can stay high while profit falls - which is usually the more reassuring of the two.
Shareholders' equity
Is CRSP's shareholder equity (book value) growing?
Period
Equity ($)
2013
-581,000
2014
-7.0M
2015
-29.1M
2016
232.8M
2017
187.8M
2018
392.2M
2019
939.4M
2020
1.66B
2021
2.40B
2022
1.88B
2023
1.88B
2024
1.93B
2025
1.92B
2026
1.75B
→The company's own capital shrank from $1.9B in 2023 to $1.7B (-7%). Buybacks or losses are drawing the buffer down - the distinction matters.
What this measures
What would be left for shareholders if every asset were sold at its book value and every debt repaid. Book value, in other words.
What good looks like. Equity growing as retained profits build up, unless the company is deliberately returning more than it earns.
If it rises or falls. Equity falls for two very different reasons: buybacks, which return money to you, and losses, which do not. The distinction is the whole story, and negative equity means liabilities now exceed assets, which makes debt-to-equity and return on equity meaningless rather than alarming.
What does “Health” actually mean?
Health asks one question: can the business survive a bad year? We check whether near-term bills are covered, whether debt is modest and shrinking, whether earnings comfortably pay the interest, and - for loss-makers - how many years of cash are left at the current burn rate.
What comes back to shareholders is thin or stretched. Read the checks before counting on it.
+0.00%bought back, TTM, over market value
-at the current rate
$57,000dividends plus buybacks
$68Mlast 12m, dilutes the buybacks
+131.5%since 2017 (split-adjusted)
Capital returned vs stock comp
Do CRSP's buybacks and dividends outweigh the stock it issues to staff?
Year
Buybacks
Dividends
Stock comp
2,018
57,000
-
35.0M
→Shareholders received $57,000 in buybacks in 2018. Stock compensation issued $72M of new shares in the same year, offsetting 100% of that.
What this measures
Cash returned through buybacks and dividends, alongside the value of new shares issued to employees as compensation.
What good looks like. Returns comfortably larger than stock compensation, so the share count actually falls.
If it rises or falls. A company can announce billions in buybacks while issuing nearly as much stock to staff, and the two largely cancel. What reaches you is the net effect, which is why both bars are here rather than only the buyback.
Share count change (split-adjusted)
Is CRSP's share count rising or falling?
Year
Share-count change
2,018
0.1974
2,019
0.187
2,020
0.1584
2,021
0.219
2,022
-0.0329
2,023
0.019
2,024
0.0649
2,025
0.066
→The share count grew 6.6% in 2025, averaging 5.0% a year over three years. Your slice of the company shrinks by that much each year unless earnings grow faster.
What this measures
The yearly change in the number of shares in issue, adjusted for splits so the years compare. A bar below zero is a falling share count, usually from buybacks; above zero, new shares were issued.
What good looks like. A flat or falling share count. Falling means each share you hold owns a little more of the business every year.
If it rises or falls. A rising count divides the same business among more owners, so your slice shrinks unless profits grow faster. This is the most direct chart on the page: it is your ownership, measured.
Dilution against what it bought
Has CRSP's revenue per share grown faster than its share count?
Change since 2017. The gap between the lines is what each share gained or lost. Share counts are split-adjusted weighted averages.
Year
Share count, change since 2017
Revenue per share, change since 2017
2,017
0
0
2,018
0.1974
-0.9364
2,019
0.4213
3.9699
2,020
0.6464
-0.9893
2,021
1.007
10.1202
2,022
0.9409
-0.9849
2,023
0.9777
3.5783
2,024
1.106
-0.5678
2,025
1.2449
-0.9619
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · on the quarterly view, revenue per share is the trailing twelve months over that quarter's diluted count
→CRSP issued 124% more shares from 2017 to 2025 and revenue per share still fell 96%. On this measure the new shares have not paid for themselves.
What this measures
The share count and revenue per share over the same years, both indexed to 100 at the start, so the two lines can be compared directly.
What good looks like. The per-share line above the share-count line: whatever the company did with its shares, more business ended up behind each one.
If it rises or falls. Issuing shares is not automatically bad. It is bad when the money raised buys less growth than the dilution cost, which is exactly what the gap between these two lines shows.
Why compare buybacks with stock compensation?
A company can trumpet billions in buybacks while quietly issuing nearly as much stock to employees. What matters to you is the net effect: is the share count actually falling? If not, the 'return' is mostly recycling.
→CRSP is in a downtrend: the price is below the cloud where recent trading settled and that cloud is still falling. Both shorter readings point down as well, so nothing here disagrees with the downtrend.
How the trend above is worked out
The trend read is the daily Ichimoku picture, the same indicator drawn on the chart above. Five names, and what each one is: the TENKAN is the midpoint of the last 9 sessions' high and low, the fast line; the KIJUN is the same over 26 sessions, the slow one; the two SENKOU spans are midpoints drawn 26 sessions into the FUTURE, and the band between them is the KUMO cloud - because it is drawn forward, the support for the coming weeks is already fixed and a change of its direction can be seen coming; the CHIKOU is today's close compared with the close 26 sessions back. A trend confirms itself in that order and the checks follow it: price clears the cloud, holds above both lines, the Tenkan crosses above the Kijun, the cloud ahead turns up, and the Chikou stands higher than the price a month ago. Six of six therefore means all of that at once; a price sitting inside the cloud, or below its own lines, cannot get there. The last check is the one Ichimoku cannot answer - whether the S&P 500 did better over 12 months (252 sessions), measured on the SPY ETF with dividends included, on the same adjusted basis as the stock's own price. Our figures are the last close we hold, refreshed every trading night; the chart is live. None of this says anything about the business, and it is not advice.
Are CRSP's insiders buying or selling shares with their own money?
Month
Buys ($)
Sells ($)
2024-01
0
4.3M
2024-02
0
2.3M
2024-03
0
3.1M
2024-04
0
1.2M
2024-05
0
0
2024-06
0
188,799
2024-07
0
0
2024-08
0
0
2024-09
0
0
2024-10
0
249,079
2024-11
0
1.7M
2024-12
0
826,565
2025-01
0
0
2025-02
313,948
2.7M
2025-03
0
1.7M
2025-04
49,704
0
2025-05
0
141,316
2025-06
0
0
2025-07
51.5M
0
2025-08
1.1M
760,660
2025-09
0
0
2025-10
0
3.8M
2025-11
0
0
2025-12
0
559,549
2026-01
0
9.1M
2026-02
0
477,374
2026-03
0
2.8M
2026-04
0
0
2026-05
0
210,577
2026-06
0
0
2026-07
0
0
2026-08
0
0
2026-09
0
1.4M
2026-10
0
1.1M
→Since January 2024, insiders bought $53M and sold $38M on the open market, a net purchase of $15M. A further 68 transactions were grants, option exercises or tax withholding, which say nothing either way.
What this measures
Open-market buys and sells by the company's own officers and directors, from their Form 4 filings. Grants, option exercises and shares withheld for tax are excluded, because they are compensation rather than decisions.
What good looks like. Buying with their own money, which is the one insider action that is hard to explain away.
If it rises or falls. Selling is weak evidence: insiders sell to diversify, to buy houses, and on pre-scheduled plans set months ahead. Buying is stronger evidence, because there is only one reason to do it. The absence of any buying over a long stretch is itself worth noticing.
The record
Who did what, exactly?
Date
Insider
Role
Type
Shares
Price
Value
2026-10-14
Simeon George
Director
exercise
30,000
$14.00
$420,000
2026-10-14
Simeon George
Director
SELL
14,514
$49.63
$720,373
2026-10-14
James R. Kasinger
General Counsel and Secretary
SELL
1,040
$49.26
$51,230
2026-10-14
Samarth Kulkarni
Chief Executive Officer
SELL
4,098
$49.26
$201,867
2026-10-06
James R. Kasinger
General Counsel and Secretary
exercise
1,990
$13.62
$27,104
2026-10-06
James R. Kasinger
General Counsel and Secretary
SELL
1,990
$60.04
$119,481
2026-09-22
James R. Kasinger
General Counsel and Secretary
exercise
10,400
$13.62
$141,648
2026-09-22
James R. Kasinger
General Counsel and Secretary
SELL
10,400
$60.24
$626,460
2026-09-17
Ali Behbahani
Director
exercise
30,000
$14.00
$420,000
2026-09-17
Ali Behbahani
Director
SELL
13,679
$57.09
$780,935
2026-05-29
Naimish Patel
Chief Medical Officer
SELL
3,786
$55.62
$210,577
2026-03-23
James R. Kasinger
General Counsel and Secretary
SELL
3,182
$46.78
$148,854
2026-03-23
Samarth Kulkarni
Chief Executive Officer
SELL
10,020
$46.78
$468,736
2026-03-23
Raju Prasad
Chief Financial Officer
SELL
3,708
$46.78
$173,460
2026-03-16
Naimish Patel
Chief Medical Officer
SELL
3,150
$48.26
$152,019
2026-03-16
Raju Prasad
Chief Financial Officer
SELL
5,848
$48.26
$282,224
2026-03-16
Raju Prasad
Chief Financial Officer
SELL
4,021
$48.26
$194,053
2026-03-16
James R. Kasinger
General Counsel and Secretary
SELL
3,450
$48.26
$166,497
2026-03-16
Samarth Kulkarni
Chief Executive Officer
SELL
10,349
$48.26
$499,443
2026-03-11
James R. Kasinger
General Counsel and Secretary
SELL
2,800
$52.80
$147,840
2026-03-11
Samarth Kulkarni
Chief Executive Officer
SELL
9,798
$52.80
$517,334
2026-02-19
Samarth Kulkarni
Chief Executive Officer
SELL
6,967
$52.58
$366,325
2026-02-19
James R. Kasinger
General Counsel and Secretary
SELL
2,112
$52.58
$111,049
2026-01-22
Raju Prasad
Chief Financial Officer
exercise
34,972
$45.15
$1.58M
2026-01-22
Raju Prasad
Chief Financial Officer
SELL
34,972
$60.19
$2.1M
2026-01-22
Samarth Kulkarni
Chief Executive Officer
SELL
60,000
$60.23
$3.61M
2026-01-20
Samarth Kulkarni
Chief Executive Officer
SELL
21,433
$51.61
$1.11M
2026-01-20
Samarth Kulkarni
Chief Executive Officer
SELL
8,567
$52.10
$446,341
2026-01-06
Raju Prasad
Chief Financial Officer
exercise
23,361
$45.15
$1.05M
2026-01-06
Raju Prasad
Chief Financial Officer
exercise
6,339
$44.31
$280,881
2026-01-06
Raju Prasad
Chief Financial Officer
SELL
18,933
$60.18
$1.14M
2026-01-06
Raju Prasad
Chief Financial Officer
SELL
5,004
$60.00
$300,240
2026-01-06
Raju Prasad
Chief Financial Officer
SELL
5,763
$60.21
$347,010
2025-12-22
Raju Prasad
Chief Financial Officer
SELL
3,528
$55.10
$194,401
2025-12-22
Raju Prasad
Chief Financial Officer
SELL
5,472
$56.33
$308,262
2025-12-22
Raju Prasad
Chief Financial Officer
SELL
1,000
$56.89
$56,886
2025-10-17
Samarth Kulkarni
Chief Executive Officer
SELL
50,895
$67.91
$3.46M
2025-10-14
Samarth Kulkarni
Chief Executive Officer
SELL
4,242
$66.60
$282,517
2025-10-14
James R. Kasinger
General Counsel and Secretary
SELL
1,076
$66.60
$71,662
Why do the transaction types matter so much?
Most insider filings are not trades: stock grants, option exercises and tax withholding are how executives get paid, and gifts are estate planning. The signal lives in open-market transactions - a buy means an insider chose to spend their own cash on the stock. Sells are murkier: many are pre-scheduled 10b5-1 plans set months in advance. That's why the chart counts only open-market activity, and the table labels every row.
VIII
Ownership
informational
78.9%on Form 13F, 30 June 2026
2.6%officers, directors, founders
49.2%together
1of the 18 TenQ follows
Top holders
Who owns CRISPR Therapeutics stock?
Fund managers filing Form 13F held 78.9% of the company's shares on 30 June 2026. The largest holder is ARK Investment Management LLC, with 9.8%. Insiders hold 2.6%.
#
Holder
Stake
Shares
Value
Change
1
ARK Investment Management LLCFund manager
9.78%
9.5M
$466M
-16.4%
2
BlackRock, Inc.Fund manager
8.63%
8.3M
$411M
+8.7%
3
Orbis Allan Gray LtdFund manager
5.64%
5.4M
$268M
-10.8%
4
Orbis Investment Management LtdHolds over 5% · Form 13G, 30 June 2026
5.62%
5.4M
$268M
-
5
Capital World InvestorsFund manager
4.91%
4.7M
$234M
+0.5%
6
State Street CorpFund manager
4.47%
4.3M
$213M
+8.5%
7
GSK plcFund manager
3.33%
3.2M
$159M
+0.0%
8
Geode Capital Management, LLCFund manager
2.60%
2.5M
$124M
+5.6%
9
Simeon GeorgeDirector · Form 4, 14 October 2026
2.12%
2.1M
$101M
-
10
T. Rowe Price Investment Management, Inc.Fund manager
2.12%
2.1M
$101M
-30.5%
11
SR One Capital Management, LPFund manager
2.11%
2.0M
$100M
+0.0%
12
Two Sigma Investments, LPFund manager
2.06%
2.0M
$98M
+34.1%
13
FMR LLCFund manager
1.97%
1.9M
$94M
-2.4%
14
Sumitomo Mitsui Trust Group, Inc.Fund manager
1.78%
1.7M
$85M
-7.2%
15
Amova Asset Management Americas, Inc.Fund manager
1.78%
1.7M
$85M
-7.2%
16
EcoR1 Capital, LLCFund manager
1.44%
1.4M
$68M
+0.0%
17
UBS Group AGFund manager
1.36%
1.3M
$65M
-25.3%
18
Capital International InvestorsFund manager
1.31%
1.3M
$62M
+6.9%
19
Vanguard Capital Management LLCFund manager
1.22%
1.2M
$58M
+3.4%
20
Bank of America CorpFund manager
1.19%
1.2M
$57M
+17.5%
The full list of top holders is free with an account
Source: SEC Form 13F filings for the quarter to 30 June 2026, Schedules 13D and 13G, and Form 4. Shares on today's basis, value at the latest price.
Super investors
Which super investors own CRISPR Therapeutics stock?
Cathie Wood's ARK Investment Management holds CRISPR Therapeutics, 3.4% of its portfolio, as of 30 June 2026. It is the only one of the 18 super investors TenQ follows that holds it.
Source: each firm's Form 13F for the quarter to 30 June 2026, and its Form 4 and Schedules 13D and 13G since. A weight is the holding's share of the firm's 13F portfolio. All super investors
Where does this list come from?
Fund managers with more than $100 million in US stocks report their holdings every quarter on Form 13F, up to 45 days after the quarter ends, so the fund figures are as of the last quarter end. A fund family reports as one manager, and funds together can report more than 100%: shares lent to short sellers are bought again by other funds, and both report them. Anyone holding more than 5% of a class files a Schedule 13D or 13G, and officers and directors report what they hold on Form 4 after every trade, so those rows carry their own dates. Short positions are not reported anywhere. A stake is the holder's shares as a share of all the company's shares, with other share classes converted at their market value.